Finasteride
sc-203954

Material Safety Data Sheet

Hazard Alert Code Key:  EXTREME  HIGH  MODERATE  LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Finasteride

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California 95060
800.457.3801 or 831.457.3800

EMERGENCY:
ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255
(1-800-CHEMCALL) or call +613 9873 3112

SYNONYMS

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

<table>
<thead>
<tr>
<th></th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Toxicity</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Body Contact</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Reactivity</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

CANADIAN WHMIS SYMBOLS
EMERGENCY OVERVIEW
RISK
Harmful if swallowed.
Possible risk of harm to the unborn child.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
■ Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
■ Impotence, decreased libido or decreased volume of ejaculate are the most commonly reported adverse effects of finasteride treatment. Other effects include enlargement of the breasts and breast tenderness in males, and hypersensitivity reactions including lip-swelling and skin rash. A no-effect level in clinical trials was 5 ug/day (multiple dose, 21 days).
When given to dogs and rats at doses up to 80 mg/kg/day, for 14 weeks, reduced prostrate gland weights were noted.

EYE
■ Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result.

SKIN
■ The material is not thought to be a skin irritant (as classified using animal models). Abrasive damage however, may result from prolonged exposures.
■ Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.
■ Open cuts, abraded or irritated skin should not be exposed to this material.
■ Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
■ The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
■ Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS
■ Long-term exposure to the product is not thought to produce chronic effects adverse to the health (as classified using animal models); nevertheless exposure by all routes should be minimized as a matter of course.
Results in experiments suggest that this material may cause disorders in the development of the embryo or fetus, even when no signs of poisoning show in the mother.
The patient’s sexual partner may become exposed to finasteride through the semen (small amounts have been recovered in the semen of patients receiving 5 mg/day). The material should not be handled by women who are or may become pregnant because of the possibility of absorption. Animal studies show feminisation of the male foetus.
In patients receiving treatment with finasteride, for 1 year, an increase in luteinising hormone (by 15%) and follicle-stimulating hormone (by 9%) has been described. These levels however remain within the physiological range. Circulating levels of cortisol, oestradiol, prolactin, thyroid-stimulating hormone or thyroxin are not altered.

Hypospadia (urethral opening on the underside of the penis), decreased prostatic and seminal vesicular weights, delayed preputial separation, transient nipple development and decreased anogenital distance were observed in the male off-spring of pregnant rats given finasteride. The critical period, in which these effects are induced, appears to be days 16-17 of gestation. Hypospadia observed in male rats exposed in utero are similar to those seen in male infants with a genetic deficiency of 5-alpha-reductase. The no-effect level for hypospadias was 30 ug/kg/day (1.5 mg for a 50 kg woman) and for decreased anogenital distance was 3 ug/kg/day. The lowering of dihydrotestosterone was also responsible for developmental abnormalities (e.g., feminisation of the male foetus) observed in animal studies.
Male rats receiving 80 mg/kg/day (60 times the recommended dose rate for humans) for 24 to 30 weeks showed decreases in fertility associated with decreased weight of seminal vesicles and prostrate. This effect was not seen in rabbits receiving up to 543 times the recommended dose.
In a 24-month carcinogenesis study in rats there was an increase in the incidence of follicular adenomas in male rats at doses corresponding to systemic exposures 100 times greater than that advised in human treatment. This effect appears in part to be due to increased clearance rates of thyroxine. In a 16-month study mice receiving 250 mg/kg/day showed an increase in Leydig cell adenoma whilst at 25 mg/kg/day there was an increase in Leydig cell hyperplasia. In vitro bacterial or mammalian cell mutagenesis assays are negative.
5 alpha-Reductase inhibitors may cause abnormalities of the external genitalia of a male foetus.

Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS
Section 4 - FIRST AID MEASURES

SWALLOWED
· IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. · Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:

EYE
■ If this product comes in contact with the eyes: · Wash out immediately with fresh running water. · Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

SKIN
■ If skin contact occurs: · Immediately remove all contaminated clothing, including footwear · Flush skin and hair with running water (and soap if available).

INHALED
· If dust is inhaled, remove from contaminated area. · Encourage patient to blow nose to ensure clear passage of breathing. · If irritation or discomfort persists seek medical attention.

NOTES TO PHYSICIAN
■ for poisons (where specific treatment regime is absent):

---BASIC TREATMENT---

· Establish a patent airway with suction where necessary.
· Watch for signs of respiratory insufficiency and assist ventilation as necessary.
· Treat symptomatically.

Section 5 - FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapour Pressure (mmHg)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
</tr>
</tbody>
</table>

EXTINGUISHING MEDIA
· Foam.
· Dry chemical powder.

FIRE FIGHTING
· Alert Emergency Responders and tell them location and nature of hazard.
· Wear breathing apparatus plus protective gloves.

GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS
· Combustible solid which burns but propagates flame with difficulty.
· Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), nitrogen oxides (NOx), other pyrolysis products typical of burning organic material.

May emit poisonous fumes.

FIRE INCOMPATIBILITY
■ Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

PERSONAL PROTECTION
Glasses:
Chemical goggles.
Gloves:
Respirator:
Particulate

Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS
· Clean up waste regularly and abnormal spills immediately.
· Avoid breathing dust and contact with skin and eyes.
· Wear protective clothing, gloves, safety glasses and dust respirator.
· Use dry clean up procedures and avoid generating dust.
· Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
Dampen with water to prevent dusting before sweeping.
Place in suitable containers for disposal.

MAJOR SPILLS
- Moderate hazard.
- CAUTION: Advise personnel in area.
- Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING
- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
- Do NOT cut, drill, grind or weld such containers.
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS
- Glass container.
- Polyethylene or polypropylene container.
- Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS
- Store in original containers.
- Keep containers securely sealed.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS
The following materials had no OELs on our records
- finasteride: CAS:98319-26-7

PERSONAL PROTECTION

RESPIRATOR
Particulate
Consult your EHS staff for recommendations

EYE
- When handling very small quantities of the material eye protection may not be required.
For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:
- Chemical goggles
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET
- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
  - frequency and duration of contact,
  - chemical resistance of glove material,
  - glove thickness and
  - dexterity
Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.
Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed
moisturiser is recommended.
- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.
Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.
- polychloroprene
- nitrile rubber
- butyl rubber
- fluorocautchouc
- polyvinyl chloride

Gloves should be examined for wear and/or degradation constantly.

OTHER
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit.

ENGINEERING CONTROLS
- Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
- HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

---

**Section 9 - PHYSICAL AND CHEMICAL PROPERTIES**

**PHYSICAL PROPERTIES**

Solid.
Does not mix with water.

<table>
<thead>
<tr>
<th>State</th>
<th>Divided solid</th>
<th>Molecular Weight</th>
<th>372.61</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melting Range (°F)</td>
<td>485.6-489.2</td>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not available</td>
<td>Solubility in water (g/L)</td>
<td>Partly miscible</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
<td>pH (1% solution)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available</td>
<td>pH (as supplied)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
<td>Relative Vapor Density (air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible</td>
<td>Evaporation Rate</td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>

**APPEARANCE**
White to off-white crystalline solid; does not mix well with water (50 mg/l - crystal form I). Soluble in chloroform, DMSO, ethanol, methanol, n-propanol, methylene chloride and tetrahydrofuran. Slightly soluble in 0.1N HCl, 0.1N NaOH

---

**Section 10 - CHEMICAL STABILITY**

**CONDITIONS CONTRIBUTING TO INSTABILITY**
- Presence of incompatible materials.
- Product is considered stable.

**STORAGE INCOMPATIBILITY**
- Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

---

**Section 11 - TOXICOLOGICAL INFORMATION**

**FINASTERIDE**

**TOXICITY AND IRRITATION**
FINASTERIDE:
- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.
TOXICITY

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (mouse) LD50: 486 mg/kg (female)</td>
<td></td>
</tr>
<tr>
<td>Oral (mouse) LD50: 596 mg/kg (male)</td>
<td></td>
</tr>
<tr>
<td>Oral (rat) LD50: 373 mg/kg (female)</td>
<td></td>
</tr>
<tr>
<td>Oral (rat) LD50: 828 mg/kg (male)</td>
<td></td>
</tr>
</tbody>
</table>

Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis). Maternal and paternal effects recorded.

* Merck, Sharpe and Dohme

IRRITATION

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye (rabbit): Slight irritation *</td>
<td></td>
</tr>
<tr>
<td>Skin (rabbit): Non-irritating *</td>
<td></td>
</tr>
</tbody>
</table>

Section 12 - ECOLOGICAL INFORMATION

No data

Ecotoxicity

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Persistence: Water/Soil</th>
<th>Persistence: Air</th>
<th>Bioaccumulation</th>
<th>Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td>finasteride</td>
<td>HIGH</td>
<td>LOW</td>
<td>LOW</td>
<td>LOW</td>
</tr>
</tbody>
</table>

Section 13 - DISPOSAL CONSIDERATIONS

Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

- Puncture containers to prevent re-use and bury at an authorized landfill.
- Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

- Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

finasteride (CAS: 98319-26-7) is found on the following regulatory lists;

- “Canada Controlled Drugs and Substances Act Schedule IV”

Section 16 - OTHER INFORMATION

LIMITED EVIDENCE

- Skin contact may produce health damage*.
  * (limited evidence).

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

- Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.
The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Jun-13-2009
Print Date: Nov-3-2010